AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23497560
Drug: Shape Up-LD
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shape Up-LD intervention (12 weekly sessions including healthy eating messages, advice on physical activity, and behaviour change techniques)
Trial: 21803749
Drug: Stopping NSAIDs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stopping NSAIDs (for a minimum of 5 drug half-lives)
Trial: 17313721
Drug: Chocolate milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chocolate milk (500 ml, 900 kJ)
Trial: 17313721
Drug: Cola (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cola (500 ml, 900 kJ)
Trial: 15369934
Drug: Pre-emptive antiemetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-emptive antiemetic therapy
Trial: 15369934
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no pre-emptive therapy)
Trial: 11394392
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of enamel matrix proteins (EMP), bovine porous bone mineral (BPBM), and a bioabsorbable membrane for guided tissue regeneration (GTR)
Trial: 2500361
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide 4 x 0.1 mg.day‐1
Trial: 2500361
Drug: Inhaled cromoglycate
RxNorm normalized name: cromoglycate
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled cromoglycate 4 x 2 mg.day‐1
Trial: 23646465
Drug: Live Combined
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live Combined Bifidobacterium and Lactobacillus Tablets (Control)
Trial: 17137211
Drug: Telmisartan (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (40 mg once daily for 24 weeks)
Trial: 17137211
Drug: Amlodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5 mg once daily for 24 weeks)
Trial: 11003445
Drug: Allergen-specific immunotherapy
RxNorm normalized name: Pacific halibut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergen-specific immunotherapy with birch pollen extract
Trial: 11003445
Drug: Allergen-specific immunotherapy
RxNorm normalized name: Pacific halibut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergen-specific immunotherapy with grass pollen extract
Trial: 8622574
Drug: Cortisol 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol 10 mg orally
Trial: 1315685
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg repirinast
Trial: 1315685
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg repirinast
Trial: 1315685
Drug: 450 mg
RxNorm normalized name: aspirin 450 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg repirinast
Trial: 3908675
Drug: fenoprofen calcium,
RxNorm normalized name: fenoprofen calcium, dihydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fenoprofen calcium, 200 mg
Trial: 3908675
Drug: fenoprofen calcium,
RxNorm normalized name: fenoprofen calcium, dihydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fenoprofen calcium, 400 mg
Trial: 3908675
Drug: aspirin, 650
RxNorm normalized name: Aspirin, 650 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aspirin, 650 mg
Trial: 28734107
Drug: XRNTX 380
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XRNTX 380 mg administered by gluteal injection at 4-week intervals (n=50)
Trial: 28734107
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo administered by gluteal injection at 4-week intervals (n=50)
Trial: 28734107
Drug: XRNTX 380
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XRNTX 380 mg
Trial: 26569149
Drug: Rotigotine (1‐3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine (1‐3 mg/24 h)
Trial: 24764585
Drug: Black raspberries
RxNorm normalized name: acid black 52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black raspberries (BRBs) - daily for 9 months, including BRB powder orally and two BRB suppositories at bedtime
Trial: 24764585
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo plus BRB suppositories
Trial: 24764585
Drug: Black raspberries
RxNorm normalized name: acid black 52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black raspberries (BRBs) - daily for 9 months
Trial: 20569707
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of baseline TnT and ST-segment resolution (STRes)
Trial: 15894560
Drug: Propofol-Lipuro (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol-Lipuro (3 mg/kg)
Trial: 15894560
Drug: Diprivan with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diprivan with added lidocaine (0.3 mg/kg)
Trial: 9809085
Drug: Granisetron 40
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron 40 micrograms.kg‐1 plus dexamethasone 8 mg i.v.
Trial: 665535
Drug: Placebo (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (after 3 days of therapy and again after 30 days)
Trial: 12873937
Drug: Propofol total
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol total intravenous anesthesia
Trial: 24754350
Drug: BoNT/A treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BoNT/A treatment (230 or 460 U onabotulinumtoxinA)
Trial: 22762347
Drug: 4 mm
RxNorm normalized name: potassium 8.4 MMOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mm × 32 G pen needle
Trial: 20740615
Drug: Oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide (CYC) for 1 year
Trial: 11976244
Drug: Eradication treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eradication treatment (omeprazole 20 mg, metronidazole 500 mg, and clarithromycin 250 mg for 7 days)
Trial: 11976244
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (omeprazole 20 mg, placebo metronidazole, and placebo clarithromycin for 7 days)
Trial: 1696577
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of antithrombin III and heparin
Trial: 7016248
Drug: Podophyllin treatment
RxNorm normalized name: podophyllin
DrugBank: Podophyllin (DB09094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Podophyllin treatment (10% and 25%)
Trial: 31619437
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg amoxicillin three times daily for three months
Trial: 29037637
Drug: Yoga program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga program (30 min per day, twice a week for 12 weeks)
Trial: 25646368
Drug: Debio0932 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Debio0932 at a dose of 1000 mg daily
Trial: 25646368
Drug: Debio0932 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Debio0932 at doses up to 1600 mg
Trial: 23061323
Drug: Ongoing counseling
RxNorm normalized name: Ongo-Fin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ongoing counseling and methadone maintenance therapy
Trial: 15934353
Drug: Fiber 7
RxNorm normalized name: pedi nutrit.,soy,iron,lf/fiber 7 gram-237 kcal/52 gram ORAL POWDER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fiber 7 supplement (7 g per meal twice a day)
Trial: 12447093
Drug: Lidocaine with
RxNorm normalized name: Lidocaine with Tegaderm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine with steroid
Trial: 2189591
Drug: Etoposide (VP‐16)
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide (VP‐16) 100, 150, or 225 mg/m2 infused over 2 h into the pleural space after drainage of pleural fluid
Trial: 2189591
Drug: Etoposide (VP‐16)
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide (VP‐16) 225 mg/m2
Trial: 27984230
Drug: Wound Infiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wound Infiltration (15 mL of bupivacaine 0.25% in each side of the surgical wound, total 30 mL)
Trial: 27984230
Drug: Transversus Abdominis
RxNorm normalized name: PAD,ABDOMINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transversus Abdominis Plane (TAP) Block (20 mL of bupivacaine 0.25% bilaterally, total 40 mL)
Trial: 26216675
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) 10 mg, bid for 3 months
Trial: 26216675
Drug: Indomethacin 25
RxNorm normalized name: indomethacin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 25 mg, bid for 3 months
Trial: 20801436
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone gel (TTG) pretreatment, 12.5 mg applied daily for 21 days before COS
Trial: 19373657
Drug: Thalidomide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide (200 mg/d, with dose escalation up to 1000 mg/d over 60 days)
Trial: 17302070
Drug: Pifukang lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pifukang lotion
Trial: 16476934
Drug: Tetrabenazine (TBZ),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetrabenazine (TBZ), maximum dosage of 100 mg/day for 12 weeks
Trial: 12627850
Drug: G‐CSF (lenograstim)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF (lenograstim)
Trial: 10784622
Drug: Cyclophosphamide plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide plus G-CSF (regimen C)
Trial: 10784622
Drug: Granulocyte-macrophage colony-stimulating
RxNorm normalized name: Granulocyte macrophage-colony stimulating factor
DrugBank: Molgramostim (DB12525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte-macrophage colony-stimulating factor plus G-CSF (regimen G)
Trial: 24254262
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate 400 mg bid plus amoxicillin 1 g bid plus clarithromycin 500 mg bid
Trial: 24254262
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg bid plus amoxicillin 1 g bid plus clarithromycin 500 mg bid
Trial: 17225018
Drug: Fucicort Lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fucicort Lipid cream
Trial: 17225018
Drug: Fucicort cream
RxNorm normalized name: betamethasone Topical Cream [Uticort]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fucicort cream
Trial: 14717749
Drug: Ventilation scintigraphy
RxNorm normalized name: VENTILATOR FILTER,THERMOFLO #6000S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventilation scintigraphy after inhalation of technegas
Trial: 9222077
Drug: Maalox (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maalox (30 mL) with trovafloxacin (100 mg)
Trial: 9222077
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with trovafloxacin (100 mg)
Trial: 9222077
Drug: Maalox (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maalox (30 mL) 2 h before trovafloxacin (100 mg)
Trial: 9222077
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg) with trovafloxacin (100 mg)
Trial: 24029165
Drug: Nicotine e‐cigarettes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine e‐cigarettes (16 mg)
Trial: 24029165
Drug: Nicotine patches
RxNorm normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patches (21 mg, one daily)
Trial: 24029165
Drug: Nicotine e‐cigarettes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine e‐cigarettes vs patches
Trial: 17058847
Drug: Combined Salmeterol/Fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Salmeterol/Fluticasone 50/250 mg for 6 weeks
Trial: 12752647
Drug: Glyde File
RxNorm normalized name: Chamois Glide
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glyde File Prep with 0.5 mL of 1% NaOCl irrigation after each file size and an additional final irrigation of 10 mL 1% NaOCl
Trial: 12752647
Drug: 17% EDTA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17% EDTA with 0.5 mL of 1% NaOCl irrigation after each file size and an additional final irrigation of 10 mL 17% EDTA
Trial: 12752647
Drug: 1% NaOCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% NaOCl with 0.5 mL of 1% NaOCl irrigation after each file size and an additional final irrigation of 10 mL 1% NaOCl
Trial: 3912977
Drug: Acyclovir 10
RxNorm normalized name: acyclovir 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir 10 mg/kg, 8‐hourly for 10 days
Trial: 24629989
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg/d for 30 days (group 1)
Trial: 24629989
Drug: Clopidogrel 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 150 mg/d for 30 days (group 2)
Trial: 24629989
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg/d (group 1)
Trial: 24629989
Drug: Clopidogrel 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 150 mg/d (group 2)
Trial: 20683333
Drug: Propofol-remifentanil total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol-remifentanil total intravenous anaesthesia (Group TIVA)
Trial: 19167593
Drug: NXY-059 (8-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NXY-059 (8-hour IV infusion with a 1-hour loading dose at 3x maintenance rate)
Trial: 8242282
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 2.5 l of a 2.5% glucose/0.45% NaCl solution
Trial: 8242282
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion of 100 ml 0.9% NaCl
Trial: 3741714
Drug: Pindolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (5 mg twice daily)
Trial: 30465360
Drug: Sildenafil alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil alone (2 mg/kg per dose, three times a day)
Trial: 30465360
Drug: Sildenafil plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil plus Bosentan (Sildenafil: 2 mg/kg per dose, three times a day; Bosentan: 1 mg/kg per dose, twice a day)
Trial: 24923683
Drug: Colloid-based therapy
RxNorm normalized name: colloidal oatmeal Topical Lotion [Theraplex Eczema Therapy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloid-based therapy
Trial: 24923683
Drug: Crystalloid-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalloid-based therapy
Trial: 22070352
Drug: Daily consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily consumption of apple (1-128 g), doubling every 2-3 weeks
Trial: 18194591
Drug: Carisoprodol 250-mg
RxNorm normalized name: carisoprodol 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carisoprodol 250-mg tablets
Trial: 15932830
Drug: IV fluid
RxNorm normalized name: IV fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV fluid bolus of 1,000 mL
Trial: 15932830
Drug: IV fluid
RxNorm normalized name: IV fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV fluid bolus of 500 mL
Trial: 15932830
Drug: Oxygen administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen administration at 10 L/min via nonrebreather face mask
Trial: 15932830
Drug: Oxygen administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen administration for fetuses with FSpO(2) < 40%
Trial: 15932830
Drug: Oxygen administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen administration for fetuses with FSpO(2) ≥ 40%
Trial: 12109341
Drug: Dietary supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplements (androstenedione, beta-carotene, CoQ10, garlic, soy, vitamin C and E)
Trial: 11107583
Drug: Measurement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measurement of antiacetylcholine receptor antibodies
Trial: 11107583
Drug: Diagnostic value
RxNorm normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnostic value of acetylcholine receptor antibodies measurement
Trial: 8750768
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of glipizide given 30 min before glucose ingestion
Trial: 8750768
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of glipizide ingested at 120 min during euglycemic insulin clamps
Trial: 7362734
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg nomifensine
Trial: 3265525
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg amitriptyline
Trial: 6437877
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg Epostane
Trial: 6437877
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Epostane
Trial: 29471206
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (n = 204)
Trial: 29471206
Drug: No music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No music therapy (n = 205)
Trial: 15672030
Drug: Plasma volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma volume expansion (250 mL hydroxyethyl starch 6% twice daily in 4 hours, and NaCl 0.9% between doses)
Trial: 15672030
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (NaCl 0.9% when necessary with medication)
Trial: 14683655
Drug: Whole virus
RxNorm normalized name: rabies, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole virus vaccine (7.5 microg, 15 microg, or 30 microg)
Trial: 14683655
Drug: Subunit vaccine
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subunit vaccine (7.5 microg, 15 microg, or 30 microg)
Trial: 14683655
Drug: Whole virus
RxNorm normalized name: rabies, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole virus vaccine (one dose)
Trial: 14683655
Drug: Subunit vaccine
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subunit vaccine (one dose)
Trial: 14683655
Drug: Whole virus
RxNorm normalized name: rabies, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole virus and subunit vaccines (two doses)
Trial: 31840323
Drug: Nutrition orientation
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrition orientation and a normoproteic, normocaloric nutrition supplement (group 2)
Trial: 31840323
Drug: Nutrition orientation
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrition orientation and the nutritional supplement with TGF‐Î²2 (group 3)
Trial: 22318328
Drug: Re-irradiation with
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-irradiation with a total dose of 50 Gy (25 fractions over 5 weeks) combined with 900 mg/m²/day capecitabine
Trial: 18302607
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy for insomnia (CBT-I) including stimulus control instructions, sleep restriction therapy, and sleep education and hygiene.
Trial: 15943846
Drug: Famotidine 20
RxNorm normalized name: famotidine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 20 mg/day for 4 weeks
Trial: 15943846
Drug: Mosapride citrate
RxNorm normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosapride citrate 15 mg/day for 4 weeks
Trial: 15943846
Drug: Amitriptyline 30
RxNorm normalized name: amitriptyline 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 30 mg/day for 4 weeks (second-step therapy)
Trial: 15943846
Drug: No medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medication (control for second-step therapy)
Trial: 14598618
Drug: ketamine (0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketamine (0.7 mg/kg)
Trial: 10807895
Drug: Hydrothermally processed
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrothermally processed cereals (active treatment)
Trial: 10807895
Drug: Ordinary cereals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ordinary cereals (placebo treatment)
Trial: 21914148
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam 0.015 mg/kg (Group S)
Trial: 16857659
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg estradiol valerate continuously with an addition of 10 mg medroxyprogesterone acetate (MPA) during the last 12 days of the 28‐day cycle
Trial: 9015114
Drug: Bovine and
RxNorm normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bovine and rhesus rotavirus vaccines (meta-analysis)